Share Name Share Symbol Market Type
TheraVet SA EU:ALVET Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.36% 2.73 2.72 2.80 2.75 2.70 2.70 534 12:25:54

TheraVet: Commercial Launch of BIOCERA-VET® in United Kingdom and Ireland

15/03/2022 6:30am

Business Wire

TheraVet (EU:ALVET)
Historical Stock Chart

From Feb 2022 to Feb 2023

Click Here for more TheraVet Charts.
  • Commercial launch of BIOCERA-VET® product line in United Kingdom and Ireland in accordance with the development plan announced by the company
  • Participation at the British Small Animal Veterinary Association congress in Mancherster (UK) from 24 to 26 March 2022 to support the launch

Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today the commercial launch of BIOCERA-VET® - its new generation bone substitute for bone surgery and for osteosarcoma - in the UK and Ireland.

After the launches in Belgium, France and The Netherlands in 2021, TheraVet is pursuing, as announced in its development plan, its commercial expansion strategy.

TheraVet enters the third largest European market with more than 16 million of companions (dogs and cats) in UK. By targeting this region, TheraVet is addressing a fast growing veterinary care market with an expected CAGR of +9.5% up to 20261. In 2020, the companion animal services market represented £6.2 billions, of which £2.1 billions2 dedicated to veterinary care. With over 23%3 of companion animals covered by health insurance, the UK is one of the countries with the highest coverage behind Sweden.

To optimize its commercial deployment, the company has also launched in Ireland, a market that accounts for approximately 1 million companions.

In order to support the launch of its products, TheraVet will be attending to the BSAVA (British Small Animal Veterinary Association) congress, a world-class conference in small animal veterinary medicine taking place in Manchester (UK) from 24 to 26 March 2022. This year, the conference will be also held in a hybrid format, you can attend online by registering at this link.

About TheraVet SA

TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary in Texas. For more information, visit the TheraVet website Or follow us on LinkedIn / Facebook / Twitter

_________________________________ 1 2 3

TheraVet Chief Operating Officer Sabrina Ena Tel: +32 (0) 71 96 00 43

Chief Corporate Officer Julie Winand

NewCap Investor Relations and Financial Communications Théo Martin / Olivier Bricaud Tel: +33 (0)1 44 71 94 94

Press Relations Arthur Rouillé / Ambre Delval Tel: +33 (0)1 44 71 00 15

NewCap Belgique Press Relations Laure-Eve Monfort Tél. : + 32 (0) 489 57 76 52

1 Year TheraVet Chart

1 Year TheraVet Chart

1 Month TheraVet Chart

1 Month TheraVet Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20230203 04:13:53